文献速递骨软组织肉瘤与黑色素瘤

在晚期血管肉瘤中开展试验的挑战:EORTC/STBSG的系统文献综述,以指导血管肉瘤特异性试验的开展

The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials.
PubMed 文献 · Eur J Cancer · 2024-06-29

该系统综述基于PubMed文献检索,评估晚期血管肉瘤的全身治疗现状与免疫治疗证据。化疗和TKI的ORR为12.5%至68%,PFS为2至7个月,随机试验稀少且方案异质性高、无共识标准方案。免疫治疗在回顾性和II期研究中显示鼓励性信号,但缺乏明确预测生物标志物。

要点

  • 晚期血管肉瘤现有化疗和TKI的ORR为12.5%至68%,PFS为2至7个月。
  • 多数中心一线或二线使用含多柔比星方案或紫杉醇,但方案异质性高且无共识标准。
  • 免疫治疗在回顾性和II期研究中显示鼓励性信号,皮肤和头颈部位似乎获益更多。

核心结论

  • 国际协作对于在晚期血管肉瘤中开展随机试验和评估免疫治疗疗效至关重要。

研究设计与样本

  • 本文为基于PubMed检索的文献综述,来源为EORTC/STBSG。

主要发现

  • 晚期血管肉瘤中化疗和TKI的ORR为12.5%至68%,PFS为2至7个月。
  • 比较这些治疗的随机试验很少,主要为II期试验。
  • 多数中心一线或二线提出含多柔比星方案或紫杉醇,但在肉瘤专科中心间方案异质性高且无共识标准治疗。
  • 抗PD1单药或联合抗CTLA4或TKI的回顾性和II期研究在血管肉瘤中报告了免疫治疗活性的鼓励性信号。
  • 皮肤和头颈部位似乎更多从免疫治疗获益,但任何血管肉瘤亚型均可能观察到缓解。

关键数值与推荐

  • 晚期血管肉瘤中化疗和TKI的ORR范围为12.5%至68%,PFS范围为2至7个月。

临床怎么用

  • 多数中心在晚期血管肉瘤一线或二线提出含多柔比星方案或紫杉醇。
  • 原文未据此给出推荐。

局限性

  • 在血管肉瘤中开展随机临床试验面临疾病异质性、缺乏共识标准方案、最佳免疫治疗给药不确定以及缺乏已建立的预测生物标志物的困难。
  • 在肉瘤尤其是血管肉瘤中,尚无明确建立的预测免疫治疗疗效的生物标志物;高肿瘤突变负荷和三级淋巴结构的存在正在评估中。
  • 原文结论提出需要国际协作开展随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While available systemic treatments have modest long term efficacy in advanced angiosarcoma, immunotherapy represents an interesting new therapeutic opportunity. To establish its benefit, it is required to conduct a clinical trial assessing its efficacy and toxicity compared to standard treatments. MATERIAL AND METHODS: This is a literature review from PubMed search. RESULTS: Several systemic treatments (chemotherapy and TKI) are currently used in advanced angiosarcoma with ORR ranging from 12.5 to 68 % and PFS from 2 to 7 months. However, few randomized trials, mainly phase II, has been conducted to compare these treatments. While most centers propose doxorubicin containing regimens or paclitaxel in 1st or 2nd line, a high heterogeneity of regimens administered in this setting is observed even across sarcoma specialized centers with no consensual standard treatment. Encouraging signals of immunotherapy activity have been reported in angiosarcoma from several retrospective and phase II studies assessing anti-PD1 either alone or in combination with anti CTLA4 or TKI. Although cutaneous and head and neck location seems to benefit more from immunotherapy, response may be observed in any angiosarcoma subtype. In sarcoma in general and AS in particular, no biomarker has been clearly established to predict the efficacy of immunotherapy: high tumor mutational burden and presence of tertiary lymphoid structures are under assessment. DISCUSSION: Even essential, developing a randomized clinical trial in AS struggles with the heterogeneity of the disease, the lack of consensual standard regimen, the uncertainty on optimal immunotherapy administration and the absence of established predictive biomarkers. CONCLUSION: International collaboration is essential to run randomized trial in advanced AS and asses the efficacy of immune therapy in this rare and heterogeneous disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dufresne A, Lindner LH, Striefler J, et al. The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials. Eur J Cancer. 2024. PMID: 38954898. doi:10.1016/j.ejca.2024.114188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。